Showing results (81-90 of 153) with videos related to

Sort By:
Pageof 16
Neoplasia (New York, N.Y.)|May 14, 2008
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnoverZhong Dong, Allen D Saliganan, Hong Meng, et al.
Urology|May 29, 2002
Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysisIsaac J Powell, Jyotirmoy Dey, Amanda Dudley, et al.
Molecular Cancer|November 5, 2016
Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasisM Katie Conley-LaComb, Louie Semaan, Rajareddy Singareddy, et al.
Urology|April 21, 2007
Heterogeneous activation of MMP-9 due to prostate cancer-bone interactionChristoph Wiesner, R Daniel Bonfil, Zhong Dong, et al.
BMC Urology|June 6, 2018
Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort studyFuraha Kariburyo, Yuexi Wang, I-Ning Elaine Cheng, et al.
Urology|June 4, 1998
Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancerE L Gheiler, M V Tefilli, R Tiguert, et al.
Human Pathology|March 24, 1999
Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal originM M Kattar, D J Grignon, J N Eble, et al.
The Prostate|April 25, 2022
The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillanceMichael Wang, Ji Qi, Arvin K George, et al.
The Prostate|December 2, 2021
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomyRohith Arcot, Michael L Cher, Ji Qi, et al.
The Journal of Urology|May 19, 2009
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancerUlka N Vaishampayan, Shanthi Marur, Lance K Heilbrun, et al.
Pageof 16